Nemolizumab

Drug Profile

Nemolizumab

Alternative Names: Anti-IL-31-receptor-monoclonal-antibody; CD-14152; CIM-331; IL-31RA monoclonal antibody - Chugai

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Maruho
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Interleukin 31 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Pruritus

Most Recent Events

  • 01 Oct 2017 Phase-I clinical trials in Atopic dermatitis (In children, Treatment-experienced) in Japan (SC) (JapicCTI-173741)
  • 01 Oct 2017 Phase-III clinical trials in Atopic dermatitis (In adolescents, In adults, Treatment-experienced) in Japan (SC) (JapicCTI-173740)
  • 14 Jun 2017 Galderma initiates a phase II trial for Atopic dermatitis (Treatment-experienced) in USA (NCT03100344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top